08:27 AM EDT, 10/10/2024 (MT Newswires) -- Immatics ( IMTX ) said Thursday that its ACTengine IMA203 TCR-T therapy demonstrated a 54% confirmed objective response rate in metastatic melanoma patients in an updated phase 1b trial.

The clinical-stage company said the data also showed a median progression-free survival of six months, with a subgroup of patients seeing over 50% tumor reduction and a median PFS of 13.4 months. There were no treatment-related Grade 5 adverse events reported.

Immatics ( IMTX ) said that, based on the phase 1b results, the company will proceed directly to a late-stage trial, which is slated to start in December.

The company said it plans to complete patient enrollment by 2026 and aims to submit a Biologics License Application for final approval in early 2027.

Shares of Immatics ( IMTX ) were down more than 13% in recent premarket activity.

Price: 9.61, Change: -1.46, Percent Change: -13.19